Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Cancer Vaccine
Treatment CSC-DC
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature PD-L1
Official Symbol CD274
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description In addition, after ALDHhigh-DC vaccination, PD-L1 expression on ALDHhigh cells (CSC) was decreased to 5.3% compared to PBS (17.2%), H-DC (8.3%) or ALDHlow-DC (11.4%) treatment. Similarly, PD-L1 expression on ALDHlow cells (non-CSC) was decreased after ALDHhigh-DC vaccination to 4.5% compared to PBS (8.2%), H-DC (6.2%) or ALDHlow-DC (7.6%) treatment. Statistically, when the mean+/-SE of the three experiments’ data were compared, ALDHhigh-DC vaccination significantly (p<0.05) reduced the PD-L1 expression on both ALDHhigh cells (CSC) and ALDHlow (non-CSC) cells.
PMID 27325649
Title Therapeutic Efficacy of Cancer Stem Cell Vaccines in the Adjuvant Setting